New once a day, fixed dose antimalarial is now available for adults and childrenBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39139.346782.DB (Published 01 March 2007) Cite this as: BMJ 2007;334:443
- Anne Griffin
A new antimalarial combination treatment to be taken as a fixed dose once a day has been developed by a non-profit organisation for use in developing countries. The combination of artesunate and amodiaquine will be known by the brand name Coarsucam in private sector sales.
The non-patented drug is the first result of the drugs for neglected diseases initiative (DNDi), a non-profit product development organisation, and was produced in partnership with one of the world's largest drug companies, Sanofi-Aventis. Two other major sources of funding were Médecins Sans Frontières and the European Commission.
“Tens of millions of people could benefit from this treatment each year,” said Bernard Pécoul, executive director of the initiative, in a statement. “The new artesunate-amodiaquine fixed dose combination has been adapted to patients' needs.” …
Log in using your username and password
Log in through your institution
Sign up for a free trial